Opinion|Videos|February 17, 2025
Approach to HER2+ Metastatic Disease Treatment
Panelists discuss how; the treatment of HER2-positive metastatic breast cancer typically involves HER2-targeted therapies combined with chemotherapy. First-line treatment usually consists of trastuzumab plus pertuzumab with a taxane. Subsequent lines may include T-DM1, tucatinib-based combinations, or other HER2-directed therapies, with treatment selection guided by disease characteristics and prior therapy response.
Advertisement
Advertisement
Related to this article
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
2
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
3
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5